

Hernan Carol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6914178/publications.pdf>

Version: 2024-02-01

73
papers

3,683
citations

109321

35
h-index

133252

59
g-index

74
all docs

74
docs citations

74
times ranked

5138
citing authors

#	ARTICLE	IF	CITATIONS
1	The pediatric preclinical testing program: Description of models and early testing results. <i>Pediatric Blood and Cancer</i> , 2007, 49, 928-940.	1.5	430
2	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). <i>Pediatric Blood and Cancer</i> , 2010, 55, 26-34.	1.5	195
3	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF1 receptor by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1190-1197.	1.5	168
4	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 799-805.	1.5	162
5	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. <i>Blood</i> , 2016, 128, 1382-1395.	1.4	148
6	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 37-45.	1.5	112
7	Initial testing (stage 1) of the BH3 mimetic ABT263 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1181-1189.	1.5	108
8	Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. <i>PLoS ONE</i> , 2011, 6, e23108.	2.5	108
9	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. <i>Clinical Cancer Research</i> , 2015, 21, 819-832.	7.0	100
10	Initial testing (stage 1) of AZD6244 (ARRY142886) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 668-677.	1.5	94
11	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 101-112.	4.1	89
12	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1291-1304.	2.3	88
13	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1325-1332.	1.5	77
14	Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 636-639.	1.5	73
15	Initial testing (stage 1) of the IGF1 receptor inhibitor BMS754807 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2011, 56, 595-603.	1.5	67
16	Cell and Molecular Determinants of <i>In Vivo</i> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 4520-4531.	7.0	67
17	The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 1795-1805.	7.0	66
18	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional <i>in vivo</i> response to BMN 673. <i>Pediatric Blood and Cancer</i> , 2015, 62, 91-98.	1.5	65

#	ARTICLE	IF	CITATIONS
19	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). <i>Clinical Cancer Research</i> , 2019, 25, 3229-3238.	7.0	61
20	Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine. <i>Vaccine</i> , 2000, 19, 460-469.	3.8	57
21	Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 633-641.	1.5	55
22	Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2009, 53, 505-508.	1.5	54
23	Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1126-1133.	1.5	51
24	AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1193-1202.	1.4	50
25	Evaluation of the <i>In Vitro</i> and <i>In Vivo</i> Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 364-374.	4.1	49
26	Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts. <i>PLoS ONE</i> , 2012, 7, e33894.	2.5	49
27	TriKEs and BiKEs join CARs on the cancer immunotherapy highway. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2790-2796.	3.3	47
28	Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 158-164.	1.5	46
29	Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1329-1337.	1.5	43
30	Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 1395-1405.	7.0	43
31	Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1255-1263.	1.5	40
32	Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 916-923.	1.5	39
33	Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1266-1274.	1.5	38
34	Initial testing of topotecan by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 54, 707-715.	1.5	37
35	Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 245-252.	1.5	37
36	Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 518-524.	1.5	36

#	ARTICLE	IF	CITATIONS
37	Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 191-199.	1.5	35
38	Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17 β -DMAG,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.5	31
39	Initial testing of the hypoxia α -activated prodrug PR α 104 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2011, 57, 443-453.	1.5	31
40	Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a β -secretase inhibitor targeting notch signaling. <i>Pediatric Blood and Cancer</i> , 2012, 58, 815-818.	1.5	31
41	Initial testing of the investigational NEDD8 α -activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 246-253.	1.5	30
42	A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with <i>Echinococcus granulosus</i> surface antigens iscoms. <i>Veterinary Immunology and Immunopathology</i> , 1998, 65, 29-41.	1.2	29
43	Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2009, 53, 594-598.	1.5	28
44	Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT α 330): A report from the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2016, 63, 276-286.	1.5	28
45	Initial Testing (Stage 1) of MK α 242 α "A Novel MDM2 Inhibitor α "by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1744-1752.	1.5	27
46	Intranasal immunization of mice with <i>Echinococcus granulosus</i> surface antigens Iscoms evokes a strong immune response, biased towards glucidic epitopes. <i>Parasite Immunology</i> , 1997, 19, 197-205.	1.5	26
47	Initial testing of JNJ α 26854165 (Serdemetan) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 329-332.	1.5	22
48	<i>Echinococcus granulosus</i> : Induction of T-independent antibody response against protoscolex glycoconjugates in early experimental infection. <i>Experimental Parasitology</i> , 2008, 119, 460-466.	1.2	20
49	Initial testing (stage 1) of SGI α 1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 749-752.	1.5	20
50	Efficacy of CPX α 351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2015, 62, 65-71.	1.5	20
51	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. <i>Cancer Research</i> , 2016, 76, 4579-4591.	0.9	20
52	Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26304.	1.5	20
53	Initial testing (stage 1) of the phosphatidylinositol 3 α 2 kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 791-798.	1.5	19
54	Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1486-1489.	1.5	19

#	ARTICLE	IF	CITATIONS
55	Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2011, 57, 268-274.	1.5	18
56	Lack of interspecies barriers in anti-Id stimulated antibody production against <i>Echinococcus granulosus</i> antigens. <i>Parasite Immunology</i> , 1989, 11, 183-195.	1.5	16
57	Testing of the topoisomerase 1 inhibitor Genzâ€644282 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 200-209.	1.5	16
58	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. <i>Clinical Cancer Research</i> , 2017, 23, 3744-3755.	7.0	16
59	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26263.	1.5	15
60	Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 185-188.	1.5	14
61	Initial testing (stage 1) of mapatumumab (HGSâ€ETR1) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 54, 307-310.	1.5	13
62	Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 783-790.	1.5	13
63	Fcâ€binding molecules specific for human IgG1 and IgG3 are present in <i>Echinococcus granulosus</i> protoscolexes. <i>Parasite Immunology</i> , 1998, 20, 399-404.	1.5	11
64	Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, E42-5.	1.5	11
65	Initial testing of aplidin by the pediatric preâ€clinical testing program. <i>Pediatric Blood and Cancer</i> , 2009, 53, 509-512.	1.5	10
66	Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1106-1109.	1.5	9
67	Initial testing (stage 1) of the notch inhibitor PFâ€03084014, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1493-1496.	1.5	6
68	Initial testing of lenalidomide by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2011, 57, 606-611.	1.5	4
69	Evolution of IgG antibody response against <i>Toxoplasma gondii</i> tissue cyst in acute and chronic human infections. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 1998, 40, 77-84.	1.1	2
70	Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 3562-3562.	1.4	2
71	Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia. <i>British Journal of Cancer</i> , 2020, 123, 742-751.	6.4	1
72	Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2016, 63, 443-450.	1.5	0

#	ARTICLE	IF	CITATIONS
73	Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104. Blood, 2010, 116, 868-868.	1.4	0